Immune Checkpoint Inhibitor Therapy 2024
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (15 January 2024) | Viewed by 315
Special Issue Editor
Interests: immunotherapy; immunocheckpoints; cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunotherapy has provoked a paradigm shift in the treatment of cancer. Since 2013, we have known that immunotherapy is fundamental to the treatment of tumors such as melanoma, non-small cell lung carcinoma, head and neck carcinoma, and bladder carcinoma. Different immune checkpoints such as PD(L)1 or CTLA-4 inhibitors have become the first agents to obtain FDA and EMA approval for the treatment of various carcinomas. Despite all efforts, there remain some patients who are primarily resistant or who become resistant after treatment. T cell exhaustion, T regs upregulation, or MDSC activity have been proposed as the mechanisms implicated in resistance to immunotherapy agents. To overcome this lack of response to immunotherapy agents, different approaches, such as combinations with chemotherapy, radiotherapy, or targeted therapy, are under investigation. At this point, it is not only tumor mutations that are relevant to choosing the suitable treatment, but a deeper knowledge of the host immune system is also required.
Dr. Eduardo Castañón Álvarez
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
